Kymera Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Cash & Equivalents	115.78	74.53	54.09	32.59	77.79	41.26
Short-Term Investments	264.92	338.77	394.44	265.2	15.94	0
Cash & Cash Equivalents	380.69	413.3	448.53	297.79	93.73	41.26
Cash Growth	-7.89%	-7.86%	50.62%	217.71%	127.17%	-
Receivables	15	0	0	0.58	0	0.15
Other Current Assets	9.63	6.12	2.74	3.97	-0.89	0.38
Total Current Assets	405.32	419.42	451.27	302.34	92.85	41.79
Property, Plant & Equipment	101.08	22.24	21.31	20.69	22.08	2.24
Long-Term Investments	61.43	152.33	125.19	162.53	0	0
Other Long-Term Assets	7.93	9.15	8.14	1.62	1.77	0.2
Total Long-Term Assets	170.44	183.72	154.63	184.84	23.86	2.44
Total Assets	575.76	603.13	605.91	487.18	116.7	44.23
Accounts Payable	7.08	4.34	4.01	4.37	3.28	2.06
Deferred Revenue	54.65	63.26	101.03	170.39	52.99	0
Current Debt	6.35	3.94	3.6	3.26	3.38	0.3
Other Current Liabilities	17.62	-0.2	-16.1	-67.4	-25.07	2.33
Total Current Liabilities	85.69	71.34	92.54	110.62	34.57	4.69
Long-Term Debt	78.33	13.39	14.36	14.73	17.82	0.39
Other Long-Term Liabilities	16.77	28.25	39.36	77.94	29.64	0.16
Total Long-Term Liabilities	95.1	41.64	53.73	92.67	47.46	0.55
Total Liabilities	180.79	112.98	146.27	203.29	82.03	5.24
Total Debt	84.67	17.34	17.96	17.99	21.19	0.7
Debt Growth	388.46%	-3.50%	-0.17%	-15.10%	2949.35%	-
Retained Earnings	-530.75	-383.79	-228.98	-128.77	-76.46	-35.21
Comprehensive Income	-0.55	-4.95	-0.66	-0.13	0.01	0
Shareholders' Equity	394.97	490.15	459.64	283.89	-74.41	-34.44
Net Cash / Debt	296.02	395.96	430.57	279.8	72.54	40.57
Net Cash / Debt Growth	-25.24%	-8.04%	53.89%	285.73%	78.82%	-
Net Cash Per Share	5.07	7.34	8.97	16.13	42.71	21.63
Working Capital	319.63	348.07	358.73	191.72	58.28	37.1
Book Value Per Share	6.77	9.09	9.58	16.36	-43.81	-18.36

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).